Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

35.66 -5.99 (-14.39%)

Streaming Delayed Price Updated: 10:23 AM EDT, Sep 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

33 34 Next >

Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data ↗

November 03, 2024

The biotech reported strong weight loss for higher doses of its experimental obesity pill.

Via Investor's Business Daily

MarketBeat Week in Review – 10/28 - 11/1

November 02, 2024

Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment

Via MarketBeat

Topics Artificial Intelligence Economy

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗

November 01, 2024

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

Via Investor's Business Daily

Viking Therapeutics Stock: A Pre-Election Bet Worth Considering

October 31, 2024

Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors

Via MarketBeat

Unpacking the Latest Options Trading Trends in Viking Therapeutics ↗

October 29, 2024

Via Benzinga

Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today ↗

October 28, 2024

Via Benzinga

3 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 24, 2024

Via Benzinga

This High-Flying Stock Just Became a Better Buy ↗

October 31, 2024

It might not be too late to get in on the party.

Via The Motley Fool

Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution? ↗

October 27, 2024

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

Via The Motley Fool

S&P 500, Nasdaq Rise Sharply Ending 3-Day Losing Streak; Viking Therapeutics Surge, While Capri’s Shares Slump ↗

October 25, 2024

US benchmark equity averages rose on Friday as the market ended a three-day losing streak.

Via Talk Markets

Topics Stocks

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review ↗

October 25, 2024

The major indexes were mixed for the week.

Via Investor's Business Daily

An Overview of Viking Therapeutics's Earnings ↗

October 22, 2024

Via Benzinga

Market Whales and Their Recent Bets on VKTX Options ↗

October 22, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years ↗

October 10, 2024

Via Benzinga

Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday ↗

October 24, 2024

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.

Via The Motley Fool

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday ↗

October 24, 2024

Via Benzinga

How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet ↗

October 24, 2024

Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss.

Via Investor's Business Daily

3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia) ↗

October 24, 2024

Regardless of who wins the presidency, investors are better off focusing on top growth stocks.

Via The Motley Fool

Viking Therapeutics Unusual Options Activity ↗

October 08, 2024

Via Benzinga

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains? ↗

October 22, 2024

Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD.

Via Benzinga

Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future ↗

October 17, 2024

Viking recently announced the results of an early-stage clinical trial for VK0214.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗

October 14, 2024

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Via Investor's Business Daily

Where Will Viking Therapeutics Be in 5 Years? ↗

October 14, 2024

We could be witnessing the birth of a major player in the biotech industry.

Via The Motley Fool

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics ↗

October 13, 2024

It's hard to go wrong with either company, but one is more appealing.

Via The Motley Fool

The Ultimate Biotech Stock to Buy With $100 Right Now ↗

October 12, 2024

This company is operating in one of today's hottest markets.

Via The Motley Fool

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams ↗

October 09, 2024

Viking Therapeutics' VK0214 Phase 1b trial in X-ALD patients showed significant reductions in VLCFAs and other lipids, while demonstrating safety. Analyst sees potential revenue upside with continued...

Via Benzinga

2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts ↗

October 07, 2024

The investment bank analysts who follow these stocks think they can soar even further, with some caveats.

Via The Motley Fool

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

All News about Viking Therapeutics, Inc. - Common Stock

Starting at /week.